Objective: Beside the stimulant medications such as Methylphenidate and Amphetamine also antidepressants, especially Atomoxetine, have demonstrated some benefit in the treatment of ADHD. Agomelatine is a new antidepressant with additional affinities to the melatonergic system. Because of the fact, that ADHD is often associated with sleep disorders, we assumed, that it might be a therapeutic alternative also for ADHD. Method: This assumption was proved in ten ADHD patients in a placebo controlled manner. Results: Agomelatine’s effect was superior to that of placebo, but seems to be less than that of Methylphenidate or placebo. Conclusion: When ADHD therapy with Methylphenidate or Atomoxetine is not indicated e.g. because of adverse side effects and if an ADHD patient suffers from additional sleep disorders, Agomelatine might be a helpful therapeutic alternative.